Human epidermal growth factor receptor 2 (HER2) overexpression (encoded by the ERBB2 gene) has long been a prognostic marker and predictive tool in the treatment of breast cancer, and more recently in esophagogastric cancer 2,3. This evidence concerns the gene ERBB2 and breast cancer.